Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Estrogen Receptor Negative|HER2/Neu Negative|Metastatic Breast Cancer|Progesterone Receptor Negative|Recurrent Breast Carcinoma|Triple Negative Breast Cancer
Interventions: BIOLOGICAL: Pembrolizumab|DRUG: Cisplatin
Sponsor: University of Washington
Collaborators: Merck Sharp & Dohme LLC